Nucleic Acid Therapeutics Market Updates

Global Nucleic Acid Therapeutics Market size was valued at USD 5.9 billion in 2023 and is poised to grow from USD 6.7 billion in 2024 to USD 18.59 billion by 2032, growing at a CAGR of 13.6% during the forecast period (2025-2032).

The competitive environment of the Global Nucleic Acid Therapeutics Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. 'Wave Life Science Ltd. (Singapore) ', 'Imugene (Australia) ', 'Aileron Therapeutics Inc. (US) ', 'BioNTech SE (Germany) ', 'Protagonist Therapeutics Inc. (US) ', 'Replicate Bioscience Inc. (US) ', 'Eli Lilly and Company (US) ', 'Copernicus Therapeutics Inc. (US) ', 'Invio Pharmaceuticals Inc. (US) ', 'Benitec Biopharma (Australia) ', 'Alnylam Pharmaceuticals (US) ', 'Zydus Cadila (India) ', 'Excision BioTherapeutics (US) ', 'Pfizer Inc. (US) ', 'Rhythm Pharmaceuticals Inc. (US) ', 'Axcella Health Inc. (US)'

Advances in molecular technologies and ongoing research on omics have led many companies to invest heavily in it. The nucleic acid-based therapeutics market is highly competitive and market share is gained through multiple business strategies. Acquisitions, partnerships or collaborations are key sources of revenue in the marketplace. For example, in August 2022, Merck & Co. will launch a $1. announced a new therapeutic RNA collaboration with Orna Therapeutics. This collaboration includes the discovery, development and commercialization of novel RNA-based therapies for vaccines, infectious diseases, and oncology programs.

Increased Investment in Healthcare Services to Increase Market Growth: Increased investment in healthcare has also accelerated the pace of research into many diseases and illnesses. Research efforts to improve health facilities have increased due to the increasing prevalence of genetic abnormalities and chronic diseases in the population.

North America is predicted to lead the market owing to factors such as high prevalence of chronic diseases such as cancer and diabetes, growing availability of targeted and customized drugs, and supportive government efforts, according to January 2022 CDC National Diabetes Statistical Report More than 130 shows it people in the United States have diabetes. The United States dominates the North American markets.